Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Advertising & Marketing

Sales

Legal & Regulatory

Acquisition & Integration

Goodwill impairment

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Teladoc

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002, by George Byron Brooks and Gary Wald and is headquartered in Purchase, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teladoc reports solid Q4 growth, eyes revenue optimization strategies

Teladoc's Q4 performance showed revenue growth and margin focus, with BetterHelp contributing significantly to profitability.
The company's strategic focus on virtual care expansion and revenue optimization positions Teladoc for continued success in the healthcare market.
While facing internal restructuring challenges, Teladoc's emphasis on growth drivers and operational efficiency presents opportunities for future growth and market leadership.

Teladoc Health excels in Q1, eyes growth and efficiency

Teladoc Health's Q1 performance was strong, with revenue exceeding expectations.
The company is focused on efficiency, innovation, and driving value in virtual care.
BetterHelp segment showed growth and stability, with improving margins expected.
Opportunities exist to capitalize on ad pricing stability and consumer behavior trends.

Teladoc surpasses revenue expectations, focuses on innovation and growth

Teladoc's Q2 performance exceeded expectations, with strong revenue growth and improved margins in both segments. The company's strategic focus on whole-person care, weight management, and AI enhancements positions it well for future growth. Challenges include managing drug costs and private company valuations, while opportunities lie in virtual care demand and strategic M&A.
Teladoc's financial strength, commitment to innovation, and focus on efficiency improvements are key strengths driving its performance. The company's ability to navigate challenges and capitalize on opportunities in the evolving healthcare landscape underscores its resilience and growth potential.

Teladoc Health surpasses Q3 expectations, eyes margin expansion in '24

Teladoc Health's Q3 performance exceeded expectations, driven by revenue growth and margin improvements.
The company is focused on enhancing cost efficiencies, profitability, and driving margin expansion.
Stable pricing environment and strong client demand present opportunities for future growth.
Operational review and strategic initiatives position Teladoc for continued success in the healthcare sector.

Teladoc reports robust 2023 earnings, eyes growth amid marketing challenges

Teladoc delivered strong financial performance in 2023 with notable growth in adjusted EBITDA and revenue. The company faces challenges in BetterHelp marketing yields and delayed consumer engagement efforts.
However, Teladoc's strategic strengths lie in its long-term outlook for revenue growth, margin expansion, and cost-saving initiatives. Opportunities exist in optimizing sales force structure and capital deployment for future growth.
Overall, Teladoc's focus on profitability, growth optimization, and strategic capital allocation positions it well for sustained success in the telehealth industry.

Teladoc Health reports solid Q1 performance amidst revenue challenges

Teladoc Health's Q1 2024 performance showcased revenue growth in Integrated Care but challenges in BetterHelp segment revenue and margin management.
The company's financial strength, product portfolio, and cost initiatives position it well for growth opportunities and strategic market positioning.
Addressing challenges in ad spend management and focusing on international market efficiency are key to unlocking growth potential and improving financial performance.
Overall, Teladoc's performance, strengths, challenges, and opportunities reflect a dynamic landscape with strategic focus on sustainable growth and operational efficiency.

Teladoc Health reports Q2 revenue dip, EBITDA growth; addresses challenges

Teladoc Health's Q2 2024 performance showed mixed results with revenue decline but EBITDA growth. The company is leveraging strengths in patient safety and technology while addressing challenges in customer acquisition costs. Opportunities lie in operational efficiency, insurance coverage access, and international expansion.

Teladoc Health reports Q3 revenue decline but strategic growth

Teladoc Health's Q3 2024 performance reflects mixed results with revenue decline but strategic growth in the Integrated Care segment.
The company's focus on customer-centric strategies, technology, and clinical excellence positions it well for future success and market leadership.
Challenges in revenue decline and expense management require Teladoc Health to balance short-term financial performance with long-term growth objectives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002, by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in Purchase, NY.

NEW YORK, NY / ACCESSWIRE / June 17, 2024 / If you suffered a loss on your Teladoc Health, Inc. (NYSE:TDOC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/teladoc-health-inc-lawsuit-submission-form?prid=85880&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Teladoc Health, Inc. (TDOC) Shareholders

NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Teladoc Health, Inc. (NYSE: TDOC) between November 2, 2022 and February 20, 2024, both dates inclusive (the “Class Period”), of the important July 16, 2024 lead plaintiff deadline.

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Teladoc Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TDOC

DocuSign

Snowflake

Navigating the tech industry in the ever-changing world of investments demands a sharp eye for growth potential and resiliency. Picking tech stocks to buy that show steadiness and potential when the market fluctuates is critical.

3 Tech Stock Leaders Set to Profit After the Pullback

NEW YORK, NY / ACCESSWIRE / June 14, 2024 / If you suffered a loss on your Teladoc Health, Inc. (NYSE:TDOC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/teladoc-health-inc-lawsuit-submission-form?prid=85551&wire=1 or contact Joseph E. Levi, Esq.

Investors who lost money on Teladoc Health, Inc. (TDOC) should contact Levi & Korsinsky about pending Class Action - TDOC

NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Teladoc Health, Inc. (NYSE: TDOC) between November 2, 2022 and February 20, 2024, both dates inclusive (the “Class Period”), of the important July 16, 2024 lead plaintiff deadline.

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Teladoc Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TDOC

NEW YORK, NY / ACCESSWIRE / June 13, 2024 / If you suffered a loss on your Teladoc Health, Inc. (NYSE:TDOC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/teladoc-health-inc-lawsuit-submission-form?prid=85395&wire=1 or contact Joseph E. Levi, Esq.

Shareholders That Lost Money on Teladoc Health, Inc.(TDOC) Should Contact Levi & Korsinsky About Pending Class Action - TDOC

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of stock of Teladoc Health, Inc. (NYSE: TDOC) between November 2, 2022 and February 20, 2024. Teladoc describes itself as a “direct-to-consumer, online health service.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegati.

Rosen Law Firm Urges Teladoc Health, Inc. (TDOC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

NEW YORK, NY / ACCESSWIRE / June 11, 2024 / If you suffered a loss on your Teladoc Health, Inc. (NYSE:TDOC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/teladoc-health-inc-lawsuit-submission-form?prid=85080&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Teladoc Health, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – TDOC

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Teladoc Health, Inc. (NYSE: TDOC) between November 2, 2022 and February 20, 2024, both dates inclusive (the “Class Period”), of the important July 16, 2024 lead plaintiff deadline.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Teladoc Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TDOC

Teladoc (TDOC) concluded the recent trading session at $10.66, signifying a +0.19% move from its prior day's close.

Teladoc (TDOC) Rises Yet Lags Behind Market: Some Facts Worth Knowing

PURCHASE, NY, June 10, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today announced that its Board of Directors has appointed Charles “Chuck” Divita, III, as Chief Executive Officer, effective immediately. Concurrent with his role as CEO, Mr.

Teladoc Health Names Chuck Divita as CEO

NEW YORK--(BUSINESS WIRE)---- $TDOC #Investor--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of those who acquired Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC) securities during the period of November 2, 2022 through February 20, 2024, inclusive (“the Class Period”). Investors have until July 16, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Kirby McInerney LLP Reminds Teladoc Health, Inc. (TDOC) Investors of Class Action Filing and Encourages Investors to Contact the Firm

NEW YORK , June 10, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Teladoc Health, Inc. (NYSE: TDOC). Shareholders who purchased shares of TDOC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Lost Money on Teladoc Health, Inc.(TDOC)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm

NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Teladoc Health Inc. ("Teladoc" or the "Company") (NYSE:TDOC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Teladoc Health Inc. – TDOC

Coinbase

Roku

Cathie Wood stocks may not have as many fans today as when Wood's Ark Invest funds were putting the markets to absolute shame back in 2020. Undoubtedly, Wood may be a seasoned investor with intriguing viewpoints on disruptive innovation and the markets as a whole.

3 Cathie Wood Stocks That Could Be Coiled Springs

SAN DIEGO, June 07, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Teladoc Health, Inc. (NYSE: TDOC) common stock between November 2, 2022 and February 20, 2024. Teladoc provides direct-to-consumer, online health services.

TDOC Class Action Reminder: Contact Robbins LLP for Information About Your Rights Against Teladoc Health, Inc.

NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC) of a class action securities lawsuit.

Teladoc Health, Inc. Class Action: Levi & Korsinsky Reminds Teladoc Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 16, 2024 – TDOC

NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Teladoc Health, Inc. (NYSE: TDOC) between November 2, 2022 and February 20, 2024, both dates inclusive (the “Class Period”), of the important July 16, 2024 lead plaintiff deadline.

ROSEN, A LEADING LAW FIRM, Encourages Teladoc Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TDOC

NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Teladoc Health, Inc. (NYSE: TDOC).

The Gross Law Firm Reminds Teladoc Health, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 16, 2024 – TDOC

Inhibrx Biosciences Inc

Agilent Technologies

Exact Sciences

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)

NEW YORK , June 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Teladoc Health, Inc. (NYSE: TDOC). Shareholders who purchased shares of TDOC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Investors who lost money on Teladoc Health, Inc.(TDOC) should contact The Gross Law Firm about pending Class Action - TDOC

NEW YORK, NY / ACCESSWIRE / June 4, 2024 / If you suffered a loss on your Teladoc Health, Inc. (NYSE:TDOC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/teladoc-health-inc-lawsuit-submission-form?prid=82802&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Teladoc Health, Inc. (TDOC) - July 16, 2024 Deadline to Join – Contact Levi & Korsinsky

SAN DIEGO, CA / ACCESSWIRE / June 4, 2024 / Robbins Geller Rudman & Dowd LLP announces that purchasers of shares of Teladoc Health, Inc. (NYSE:TDOC) stock between November 2, 2022 and February 20, 2024, inclusive (the "Class Period"), have until July 16, 2024 to seek appointment as lead plaintiff of the Teladoc class action lawsuit. Captioned Stary v.

TDOC INVESTOR ALERT: Teladoc Health, Inc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK , June 4, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Teladoc Health, Inc. (NYSE: TDOC) between November 2, 2022 and February 20, 2024, both dates inclusive (the "Class Period"), of the important July 16, 2024 lead plaintiff deadline. SO WHAT: If you purchased Teladoc stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Teladoc Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TDOC

In the most recent trading session, Teladoc (TDOC) closed at $10.87, indicating a -1.9% shift from the previous trading day.

News for Teladoc Stock (TDOC)